Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial

OBJECTIVES: To assess the effects of rivastigmine on the core domains of Alzheimer’s disease. DESIGN: Prospective, randomised, multicentre, double blind, placebo controlled, parallel group trial. Patients received either placebo, 1-4 mg/day (lower dose) rivastigmine, or 6-12 mg/day (higher dose) riv...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Rösler, Michael, Anand, Ravi, Cicin-Sain, Ana, Gauthier, Serge, Agid, Yves, Dal-Bianco, Peter, Stähelin, Hannes B, Hartman, Richard, Gharabawi, Marguirguis
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BMJ Group 1999
विषय:
Papers
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC27767/
https://ncbi.nlm.nih.gov/pubmed/10066203
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन